성상세포종 시장 규모 조사 : 유형별, 치료법별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 시장 예측(2022-2032년)

Global Astrocytoma Market is valued approximately at USD 1.1 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3% over the forecast period 2024-2032. Astrocytoma, a type of brain tumor originating from astrocytes, which are a kind of glial cell in the central nervous system, has become a focal point of intense medical research due to its critical implications on human health. These tumors are notorious for their aggressive nature, with symptoms ranging from persistent headaches to more severe manifestations such as seizures, cognitive dysfunction, and motor skill impairments. The rise in the prevalence of astrocytoma, coupled with the escalation of genetic mutations leading to tumor development, is fueling market expansion. Additionally, the rising exposure to ionizing radiation, whether from medical treatments or occupational hazards, is further exacerbating the incidence of this condition, thereby augmenting the demand for innovative and effective treatment solutions.

The market is witnessing significant growth driven by the advent of proton therapy, a cutting-edge technology that delivers high doses of radiation directly to the tumor while sparing surrounding healthy tissues. This method represents a substantial improvement over traditional radiation therapy and is becoming increasingly popular. Moreover, targeted therapy is gaining traction as a method to inhibit specific molecules or pathways involved in tumor progression, offering a more personalized approach to treatment. The continuous advancements in surgical techniques, such as awake craniotomy and intraoperative MRI, are also contributing to the positive outlook of the astrocytoma market, as these innovations enable more precise and effective tumor removal while minimizing neurological damage. However, high cost of treatment procedures and limited accessibility to advanced surgical techniques are the key factors that are substantially halting the growth of the market globally.

The key regions considered for the global Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America currently holds the largest market share, underpinned by the high prevalence of anaplastic astrocytomas and substantial investments in healthcare infrastructure. Also, with growing awareness about treatment options driving market demand. Meanwhile, the Asia-Pacific region is poised for the highest growth over the forecast period, fueled by technological advancements and increased healthcare spending.

Major market player included in this report are:

• Pfizer Inc.
• Genentech, Inc.
• Novartis AG
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Celldex Therapeutics
• EirGen Pharma
• AXELAR
• Isarna Therapeutics GmbH
• PHARMA'S ALMANAC

The detailed segments and sub-segment of the market are explained below:

By Type:

• Anaplastic Astrocytomas
• Glioblastomas
• Diffuse Astrocytomas
• Pineal Astrocytic Tumors
• Drain Stem Gliomas
• Pilocytic Astrocytomas
• Subependymal Giant Cell Astrocytomas

By Treatment:

• Surgery
• Radiation
• Chemotherapy

By Application:

• Pre-registration Phase
• Clinical Trial Phase

By End User:

• Hospitals
• Specialty Clinics
• Research Centers

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Astrocytoma Market Executive Summary

• 1.1. Global Astrocytoma Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Treatment
  • 1.3.3. By Application
  • 1.3.4. By End User
  • 1.3.5. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Astrocytoma Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Astrocytoma Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Incidence of Genetic Mutations and Tumor Development
  • 3.1.2. Increasing Exposure to Ionizing Radiation
  • 3.1.3. Advancements in Proton Therapy and Targeted Therapy
• 3.2. Market Challenges
  • 3.2.1. High Cost of Treatment Procedures
  • 3.2.2. Limited Accessibility to Advanced Surgical Techniques
• 3.3. Market Opportunities
  • 3.3.1. Technological Innovations in Surgical Procedures
  • 3.3.2. Growing Investment in Healthcare Infrastructure in Emerging Markets

Chapter 4. Global Astrocytoma Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Astrocytoma Market Size & Forecasts by Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Astrocytoma Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Anaplastic Astrocytomas
  • 5.2.2. Glioblastomas
  • 5.2.3. Diffuse Astrocytomas
  • 5.2.4. Pineal Astrocytic Tumors
  • 5.2.5. Drain Stem Gliomas
  • 5.2.6. Pilocytic Astrocytomas
  • 5.2.7. Subependymal Giant Cell Astrocytomas

Chapter 6. Global Astrocytoma Market Size & Forecasts by Treatment 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Astrocytoma Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Surgery
  • 6.2.2. Radiation
  • 6.2.3. Chemotherapy

Chapter 7. Global Astrocytoma Market Size & Forecasts by Application 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Astrocytoma Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Pre-registration Phase
  • 7.2.2. Clinical Trial Phase

Chapter 8. Global Astrocytoma Market Size & Forecasts by End User 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Astrocytoma Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Hospitals
  • 8.2.2. Specialty Clinics
  • 8.2.3. Research Centers

Chapter 9. Global Astrocytoma Market Size & Forecasts by Distribution Channel 2022-2032

• 9.1. Segment Dashboard
• 9.2. Global Astrocytoma Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 9.2.1. Hospital Pharmacy
  • 9.2.2. Retail Pharmacy
  • 9.2.3. Online Pharmacy

Chapter 10. Global Astrocytoma Market Size & Forecasts by Region 2022-2032

• 10.1. North America Astrocytoma Market
  • 10.1.1. U.S. Astrocytoma Market
    • 10.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 10.1.1.2. Treatment breakdown size & forecasts, 2022-2032
    • 10.1.1.3. Application breakdown size & forecasts, 2022-2032
    • 10.1.1.4. End User breakdown size & forecasts, 2022-2032
    • 10.1.1.5. Distribution Channel breakdown size & forecasts, 2022-2032
  • 10.1.2. Canada Astrocytoma Market
    • 10.1.2.1. Type breakdown size & forecasts, 2022-2032
    • 10.1.2.2. Treatment breakdown size & forecasts, 2022-2032
    • 10.1.2.3. Application breakdown size & forecasts, 2022-2032
    • 10.1.2.4. End User breakdown size & forecasts, 2022-2032
    • 10.1.2.5. Distribution Channel breakdown size & forecasts, 2022-2032
• 10.2. Europe Astrocytoma Market
  • 10.2.1. U.K. Astrocytoma Market
  • 10.2.2. Germany Astrocytoma Market
  • 10.2.3. France Astrocytoma Market
  • 10.2.4. Spain Astrocytoma Market
  • 10.2.5. Italy Astrocytoma Market
  • 10.2.6. Rest of Europe Astrocytoma Market
• 10.3. Asia-Pacific Astrocytoma Market
  • 10.3.1. China Astrocytoma Market
  • 10.3.2. India Astrocytoma Market
  • 10.3.3. Japan Astrocytoma Market
  • 10.3.4. Australia Astrocytoma Market
  • 10.3.5. South Korea Astrocytoma Market
  • 10.3.6. Rest of Asia Pacific Astrocytoma Market
• 10.4. Latin America Astrocytoma Market
  • 10.4.1. Brazil Astrocytoma Market
  • 10.4.2. Mexico Astrocytoma Market
  • 10.4.3. Rest of Latin America Astrocytoma Market
• 10.5. Middle East & Africa Astrocytoma Market
  • 10.5.1. Saudi Arabia Astrocytoma Market
  • 10.5.2. South Africa Astrocytoma Market
  • 10.5.3. Rest of Middle East & Africa Astrocytoma Market

Chapter 11. Competitive Intelligence

• 11.1. Key Company SWOT Analysis
• 11.2. Top Market Strategies
• 11.3. Company Profiles
  • 11.3.1. Pfizer Inc.
    • 11.3.1.1. Key Information
    • 11.3.1.2. Overview
    • 11.3.1.3. Financial (Subject to Data Availability)
    • 11.3.1.4. Product Summary
    • 11.3.1.5. Market Strategies
  • 11.3.2. Genentech, Inc.
  • 11.3.3. Novartis AG
  • 11.3.4. Boehringer Ingelheim International GmbH
  • 11.3.5. Amgen Inc.
  • 11.3.6. Celldex Therapeutics
  • 11.3.7. EirGen Pharma
  • 11.3.8. AXELAR
  • 11.3.9. Isarna Therapeutics GmbH
  • 11.3.10. PHARMA'S ALMANAC

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes